|
|
|
206A PRISM BioLab Co.,LTD
|
|
| 11/13/2026 16:00 |
Notice of Expiration of the Library Screening and License Agreement with Merck Healthcare KGaA |
| 11/13/2026 16:00 |
[Summary] Non-consolidated Financial Results for the Fiscal Year Ended September 30, 2026 (Under Japanese GAAP) |
| 10/09/2026 16:00 |
Clinical Results from the Dose-Expansion Cohort of a Phase 1b_2 Study of E7386, Published in eClinicalMedicine |
| 08/14/2026 16:00 |
[Summary] Non-consolidated Financial Results for the Nine Months of the Fiscal Year Ending September 30, 2026 (Under Japanese GAAP) |
| 07/02/2026 16:00 |
Phase 1 Clinical Pharmacology Results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in The Journal of Clinical Pharmacology |
| 05/25/2026 16:00 |
Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO |
| 05/15/2026 16:00 |
Notice of Expiration of the Research and License Agreement with Boehringer Ingelheim International GmbH |
| 05/14/2026 16:00 |
[Summary] Financial Results for the Six Months Ended March 31, 2026 |
| 04/06/2026 16:00 |
Preclinical Results for E7386, Jointly Created by PRISM BioLab and Eisai, to Be Presented by Eisai at the AACR Annual Meeting |
| 03/12/2026 16:00 |
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement |
| 02/13/2026 16:30 |
[Summary] Non-consolidated Financial Results for the Three Months of the Fiscal Year Ending September 30, 2026 (Under Japanese GAAP) |
| 01/21/2026 16:00 |
Phase 1 clinical research results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in ESMO OPEN |
| 12/17/2025 16:00 |
Nonclinical research results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in Clinical Cancer Research |
| 12/17/2025 16:00 |
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets |
|